| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Previous issue > Previous issue



Table of Contents | December, 2021  Vol. 39  No.4 Previous Issue | Next Issue | Archive
In this issue:


Review Article
Abscopal effect in the radio and immunotherapy
Alina M. Pevzner, Matvey M. Tsyganov, Marina K. Ibragimova, Nikolai V. Litvyakov
Radiat Oncol J. 2021;39(4):247-253.   Published online October 25, 2021
This review is devoted to a rare in clinical practice, but promising phenomenon of regression distant non-irradiated metastases in combination therapy of cancer patients. R. H. Mole in 1953 suggested introducing the term “abscopal effect” to denote the effect of ionizing radiation “at a distance from the irradiated volume but within the same organism.” Currently, it is a hypothesis in...
Original Articles
Clinical Investigation
Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases
Ben Man Fei Cheung, Kin Sang Lau, Victor Ho Fun Lee, To Wai Leung, Feng-Ming Spring Kong, Mai Yee Luk, Kwok Keung Yuen
Radiat Oncol J. 2021;39(4):254-264.   Published online October 26, 2021

Purpose: Radiomic models elaborate geometric and texture features of tumors extracted from imaging to develop predictors for clinical outcomes. Stereotactic body radiation therapy (SBRT) has been increasingly applied in the ablative treatment of thoracic tumors. This study aims to identify predictors of treatment responses in patients affected by early stage non-small cell lung cancer (NSCLC) or pulmonary oligo-metastases treated with...
Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer
Kazuya Takeda, Haruo Matsushita, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Keiichi Jingu
Radiat Oncol J. 2021;39(4):265-269.   Published online September 3, 2021

Purpose: Re-irradiation is a treatment option for recurrent esophageal cancer patients with a history of radiotherapy, but there is a risk of severe late adverse effects. This study focused on the efficacy and safety of re-irradiation using hyperfractionated radiotherapy. Materials and Methods: Twenty-six patients who underwent re-irradiation by the hyperfraction technique using twice-daily irradiation of 1.2 Gy per fraction for...
Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with subgroup analysis between the older and young patients
Alimohammad Bananzadeh, Ali Akbar Hafezi, NamPhong Nguyen, Shapour Omidvari, Ahmad Mosalaei, Niloofar Ahmadloo, Mansour Ansari, Mohammad Mohammadianpanah
Radiat Oncol J. 2021;39(4):270-278.   Published online October 26, 2021

Purpose: This study was performed to investigate the efficacy and safety of short-course radiation therapy (SCRT) and sequential chemotherapy followed by delayed surgery in locally advancer rectal cancer with subgroup analysis between the older and young patients. Materials and Methods: In this single-arm phase II clinical trial, eligible patients with locally advanced rectal cancer (T3–4 and/or N1–2) were enrolled. All the...
Re-irradiation for recurrent or second primary head and neck cancer
Hye In Lee, Jin Ho Kim, Soon-Hyun Ahn, Eun-Jae Chung, Bhumsuk Keam, Keun-Yong Eom, Woo-Jin Jeong, Ji-Won Kim, Chan Woo Wee, Hong-Gyun Wu
Radiat Oncol J. 2021;39(4):279-287.   Published online December 7, 2021

Purpose: To investigate the efficacy and safety of intensity-modulated radiotherapy (IMRT)-based re-irradiation (reRT) for recurrent or second primary head and neck cancer (HNC). Materials and Methods: Patients who underwent IMRT-based reRT for recurrent or second primary HNC between 2007 and 2019 at two institutions were included. Medical records and dosimetric data were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), severe...
Clinical features and treatment outcomes of resected large cell neuroendocrine carcinoma of the lung
Jin Young Moon, Seo Hee Choi, Tae Hyung Kim, Joongyo Lee, Ji Hoon Pyo, Yong Tae Kim, Seo Jin Lee, Hong In Yoon, Jaeho Cho, Chang Geol Lee
Radiat Oncol J. 2021;39(4):288-296.   Published online December 8, 2021

Purpose: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade lung neuroendocrine tumor with a poor prognosis, similar to small cell lung cancer (SCLC). However, it remains unclear whether to treat LCNEC as non-small-cell lung cancer (NSCLC) or as SCLC. We reviewed our experiences to suggest appropriate treatment strategy for resected pulmonary LCNEC. Materials and Methods: Forty-four patients were treated for...
Prognostic value of the maximum standardized uptake value for the locoregional control in early glottic cancer
Donghyun Kim, Yongkan Ki, Jihyeon Joo, Hosang Jeon, Dahl Park, Jiho Nam, Wontaek Kim
Radiat Oncol J. 2021;39(4):297-303.   Published online December 14, 2021

Purpose: To evaluate the prognostic value of the pretreatment maximum standardized uptake value (SUVmax) for locoregional control (LRC) of early glottic cancer treated with primary radiotherapy. Materials and Methods: We retrospectively reviewed the medical records of 101 patients with T1-T2N0 glottic cancer treated with helical tomotherapy between 2013 and 2016. The clinical T-stages were T1 in 87 (86.1%) and T2 in...
Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection
Abhinav V. Reddy, Colin S. Hill, Shuchi Sehgal, Ding Ding, Amy Hacker-Prietz, Jin He, Lei Zheng, Joseph M. Herman, Jeffrey Meyer, Amol K. Narang
Radiat Oncol J. 2021;39(4):304-314.   Published online December 17, 2021

Purpose: The purpose of this study was to determine if somatic mutations are associated with clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) who were treated with neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT). Materials and Methods: Patients treated with neoadjuvant chemotherapy and SBRT followed by surgical resection from August...
Clinical factors affecting the determination of radiotherapy-induced skin toxicity in breast cancer
Elisa Eugenia Córdoba, Ezequiel Lacunza, Alba Mabel Güerci
Radiat Oncol J. 2021;39(4):315-323.   Published online December 24, 2021

Purpose: Radiotherapy is essential for the treatment of breast cancer (BC). However, adverse effects may occur in healthy tissue, during treatment and even after several months. Although it is known that this clinical radiosensitivity is multifactorial, the factors involved are unknown yet. In this study, we evaluated the effect of these factors on the development of radiodermatitis in patients undergoing...
Biology contribution
Gamma-ray irradiation modulates PGRMC1 expression and the number of CD56+ and FoxP3+ cells in the tumor microenvironment of endometrial endometrioid adenocarcinoma
Dmitry Aleksandrovich Zinovkin, Yulia Anatolievna Lyzikova, Eldar Arkadievich Nadyrov, Daniil Rudolfovich Petrenyov, Jale Yuzugulen, Md Zahidul Islam Pranjol
Radiat Oncol J. 2021;39(4):324-333.   Published online August 17, 2021

Purpose: Although the conventional gamma ray brachytherapy has been successful in treating endometrioid endometrial adenocarcinoma (EC), the molecular and cellular mechanisms of this anti-tumorigenic response remain unclear. Therefore, we investigated whether gamma ray irradiation induces changes in the number of FoxP3+ T-regulatory lymphocytes (Tregs), CD56+ natural killer cells (NK), and the expression of progesterone receptor membrane component 1 (PGRMC1) in...
E-Submission
Principles of Transparency and Best Practice
Author's Index
KOSRO
Journal Impact Factor 1.8
SCImago Journal & Country Rank
PubMed Central
PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Department of Radiation Oncology, Samsung Medical Center,
Proton Therapy Center, B2, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
Tel : +82-2-3410-3617
E-mail: rojeditor@gmail.com, roj@kosro.or.kr
Copyright © The Korean Society for Radiation Oncology.                      Developed in M2PI
Close layer
prev next